Lenalidomide - current understanding of mechanistic properties

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 315-326

  Tageja, Nishant ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

CLL; IMiDs; Lenalidomide; MDS; Mechanism of action; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; PERIFOSINE; POMALIDOMIDE; RAPAMYCIN; TEMSIROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RELAPSE; DOWN REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; OSTEOCLASTOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT;

EID: 79955044513     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795347487     Document Type: Review

References (97)

1. Stephens, T.; Brynner, R. Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. Cambridge, MA: Perseus Publishing; 2001.
2. Kelsey, F. Thalidomide update: Regulatory aspects. Teratology, 1988, 38, 221-226.
3. Knobloch. J.; Ruther, U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle, 2008, 7, 1121-1127.
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 18, 285(21), 1182-1186.
5. Olson, K.B.; Hall, T.C.; Horton, J.; Khung, C.L.; Hosley, H.F.; Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin. Pharmacol. Ther., 1965, 6, 292-297.
6. Grabstad H.; Golbey, R. Clinical experience with thalidomide in patients with cancer. Clin. Pharmacol. Therap., 1965, 6, 298-302.
7. Sampaio, E.; Sarno, E.; Gallily, R.; Cohn, Z.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med., 1991, 173, 699-703.
8. Muller, G.W.; Chen, R.; Huang, S.Y. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett., 1999, 9(11), 1625-1630.
9. Corral, L.G.; Haslett, P.A.J.; Muller, G.W.; Chen, R.; Wong, L.M.; Ocampo, C.J.; Patterson, R. T.; Striling, D.I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-{a}. J. Immunol., 1999, 163, 380-386.
10. Bartlett, J.B.; Dredge, K.; Dalgleish, A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer., 2004, 4, 314-322.
11. Cook, G.; Campbell, J.D. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Reviews, 1999, 13, 151-162.
12. Cook, G.; Campbell, J.D.; Carr, C.E.; Boyd, K.S.; Franklin, I.M. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J. Leuk. Biol., 1999, 66, 981-988.
13. Gorelik, L.; Flavell, R.A. Transforming growth factor-beta in Tcell biology. Nat. Rev., Immun., 2002, 2, 46-53.
14. Urashima, M.; Ogata, A.; Chauhan, D.; Hatziyanni, M.; Vidriales, M.B.; Dedera, D.A.; Schlossman, R. L; Anderson, K.C. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood, 1996, 87, 1928-1938.
15. Pratt, G. Goodyear, O.; Moss, P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol., 2007, 138(5), 563-579.
16. Mills, K.H.; Cawley, J.C. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br. J. Haematol., 1983, 53, 271-275.
17. Ogawara, H.; Handa, H.; Yamazaki, T.; Toda, T.; Yoshida, K.; Nishimoto, N.; Al-ma'Quol, W.; Kaneko, Y.; Matsushima, T.; Tsukamoto, N.; Nojima, Y.; Matsumoto, M.; Sawamura, M.; Murakami, H. High Th1/Th2 ratio in patients with multiple myeloma. Leuk. Res., 2005, 29, 135-140.
18. Rawstron, A.C.; Davies, F.E.; Owen, R.G.; English, A.; Pratt, G.; Child, J.A.; Jack, A.S.; Morgan, G.J. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br. J. Haematol., 1998, 100, 176-183.
19. Jarahian, M.; Watzl, C.; Issa, Y.; Altevogt, P.; Momburg, F. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int. J. Cancer, 2007, 120, 2625-2634.
20. Dhodapkar, M.V.; Geller, M.D.; Chang, D.H.; Shimizu, K.; Fujii, S.I.; Dhodapkar, K.M.; Krasovsky, J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med., 2003, 198, 1667-1676.
21. Brown, R.D.; Pope, B.; Murray, A.; Esdale, W.; Sze, D.M.; Gibson, J.; Ho, P.J.; Hart, D.; Joshua, D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factorbeta1 and interleukin-10. Blood, 2001, 98, 2992-2998.
22. Brown, R.; Murray, A.; Pope, B.; Sze, D.m.; Gibson, J.; Ho, P.J.; Hart, D.; Joshua, D. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br. J. Haematol., 2004, 125, 743-748.
23. Ratta, M.; Fagnoni, F.; Curti, A.; Vescovini, R.; Sansoni, P.; Oliviero, B.; Fogli, M.; Ferri, E.; Della Cuna, G.R.; Tura, S.; Baccarani, M.; Lemoli, R.M. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 2002, 100, 230-237.
24. Takahashi, A.; Kono, K.; Ichihara, F.; Sugai, H.; Fujii, H.; Matsumoto, Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother., 2004, 53, 543-550.
25. Xie, J.; Ying, W.; Freeman, M.E.; Barlogie, B.; Qing, Y. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood, 2003, 101, 4005-4012.
26. Curiel, T.J. Regulatory T-cell development: is Foxp3 the decider? Nat. Med., 2007, 13, 250-253.
27. Beyer, M.; Schultze, J.L.; Regulatory T cells in cancer. Blood, 2006, 108, 804-811.
28. Carreras, J.; Lopez-Guillermo, A.; Fox, B.C.; Colomo, L.; Martinez, A.; Roncador, G.; Montserrat, E.; Campo, E.; Banham, A.H. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108, 2957-2964.
29. Alvaro, T.; Lejeune, M.; Salvado, M.T.; Bosch, R.; Garcia, J.F.; Jaen, J.; Banham, A.H.; Roncador, G.; Montalbán, C.; Piris, M.A. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res., 2005, 11(4), 467-473.
30. Joshua, D.E.; Brown, R.D.; Ho, P.J.; Gibson, J. Regulatory T cells and multiple myeloma. Clin. Lymph. Myeloma, 2008, 8, 283-286.
31. Prabhala, R.H.; Neri, P.; Bae, J.E.; Tassone, P.; Shammas, M.A.; Allam, C.K.; Dalley, J.F.; Chauhan, D.; Blanchard, E.; Thatte, H. S. Anderson, K.C. Munshi, N.C. Dysfunctional T regulatory cells in multiple myeloma. Blood, 2006, 107, 301-304.
32. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441, 235-238.
33. Beyer, M.; Kochanek, M.; Giese, T.; Endl, E.; Weihrauch, M.R. Knolle, P.A.; Classen, S.;Schultze, J.L. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood, 2006, 107, 3940-3949.
34. Condomines, M.; Quittet, P.; Zhao-Yang L.; Nadal, L.; Latry, P.; Lopez, E.; Baudard, M.; Requirand, G.; Duperray, C.; Schved, J.F.; Rossi, J.F.; Tarte, K.; Klein, B. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J. Immunol., 2006, 176, 6631-6639.
35. LeBlanc, R.; Hideshima, T.; Catley, L.P. Shringarpure, R.; Burger, R.; Mitsiades, N. Mitsiades, C.; Cheema, P.; Chauhan, D.; Richardson, P.G.; Anderson, K.C.; Munshi, N.C. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood, 2004, 103, 1787-1790.
36. Davies, F.E.; Raje, N.; Hideshima, T.; Lentzsch, S.; Young, G.; Tai, Y.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S.P.; Richardson, P.G.; Schlossman, R.L.; Morgan, G.J.; Muller, G.W.; Stirling, D.I.; Anderson, K.C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98, 210-216.
37. Miura, Y.; Tsujioka, T.; Nishimura, Y.; Sakaguchi, H.; Maeda, M.; Hayashi, H.; Dong, M.; Hyodoh, F.; Yata, K.; Wada, H.; Sugihara, T.; Otsuki, T. TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res., 2006, 26, 4115-4124.
38. Corral, L.G.; Kaplan, G. Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis., 1999, 58(Suppl 1), 1107-1113.
39. Schafer, P.H.; Gandhi, A.K.; Loveland, M.A.; Chen, R.S.; Man, H.W.; Schnetkamp, P.P.; Wolbring, G.; Govinda, S.; Corral, L.G.; Payvandi, F.; Muller, G.W.; Stirling, D.I. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Therap., 2003, 305, 1222-1232.
40. Dredge, K.; Marriott, J.B.; Todryk, S.M.; Muller, G.W.; Chen, R.; Stirling, D.I.; Dalgleish, A.G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol., 2002, 168, 4914-4919.
41. Bartlett, J.B.; Michael, A.; Clarke, I.A.; Dredge, K.; Nicholson, S.; Kristeleit, H.; Polychronis, A.; Pandha, H.; Miller, G.W.; Stirling, D.I.; Zeldis, J.; Dalgleish, A.G. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer., 2004, 90(5), 955-961.
42. Schey, S.A.; Fields, P.; Bartlett, J.B.; Clarke, I.A.; Ashan, G.; Knight R.D.; Streetly, M.; Dalgleish, A.G. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol., 2004, 22(16), 3269-3276.
43. Payvandi, F.; Wu, L.; Naziruddin, S.D.; Haley, M.; Parton, A.; Schafer, P.H.; Chen, R.S.; Muller, G.W.; Hughes, C.C.; Stirling, D.I. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NFkappaB, OCT-1, or NF-AT. J. Interferon Cytokine Res., 2005, 25, 604-616.
44. Hayashi, T.; Hideshima, T.; Akiyama, M.; Podar. K.; Yasui, H.; Raje, N.; Kumar, S.; Chauhan, D.; Treon, S.P.; Richardson, P.; Anderson, K.C. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol., 2005, 128, 192-203.
45. Galustian, C.; Meyer, B.; Labarthe, M.C.; Dredge, K.; Klaschka, D.; Henry, J.; Todryk, S.; Chen, R.; Muller, G.; Stirling, D.; Schafer, P.; Bartlett, J. B.; Dalgleish, A.G. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother., 2009, 58, 1033-1045.
46. Galustian, C.; Meyer, B.; Labarthe, M.C.; Dredge, K.; Klaschka, D.; Henry, J.; Todryk, S.; Chen, R.; Muller, G.; Stirling, D.; Schafer, P.; Bartlett, J. B.; Dalgleish, A.G. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother., 2009, 58(7), 1033-45. Epub 2008 Nov 14.
47. Quach, H.; Ritchie, D.; Neeson, P.; Harrison, S.; Tai, T.; Tainton, K. Regulatory T cells (Treg) are Depressed in Patients with Relapsed/ Refractory Multiple Myeloma (MM) and Increases Towards Normal Range in Responding Patients Treated with Lenalidomide (LEN) [abstract]. Blood, 2008, 112, 1696a.
48. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, 441, 235-238.
49. Alsayed, Y.; Ngo, H.; Runnels, J.; Leleu, X.; Singha, U.K.; Pitsillides, C.M.; Spencer, J.A.; Kimlinger, T.; Ghobrial, J.M.; Lu, G.; Timm, M.; Kumar, A.; Côté, D.; Veilleux, I.; Hedin, K.E.; Roodman, G.D.; Witzig, T.E.; Kung, A.L.; Hideshima, T.E.; Anderson, K.C.; Lin, C.P.; Ghobrial, I.M. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood, 2007, 109, 2708-2717.
50. James, D.; Avery, E. D; Zhang, L.; Gould, J.; Greaves A.; Castro, J.E.; Rassenti, L. Z.; Kipps, T. J. Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients-In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR). Blood0, (ASH Annual Meeting Abstracts), 2009, 114, 3440.
51. Hayashi, T.; Hideshima, T.; Akiyama, M.; Podar, K.; Yasui, H.; Raje, N.; Kumar, S.; Chauhan, D.; Treon, S.P.; Richardson, P.; Anderson, K.C. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol., 2005, 128, 192-203.
52. Wu, L.; Adams, M.; Carter, T.; Chen, R.; Muller, G; Stirling, D.; Schafer, P.; Bartlett, J.B. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res., 2008, 14, 4650-4657.
53. Tai, Y.T.; Li, X.F.; Catley, L.; Coffey, R.; Breitkreutz, I.; Bae, J.; Song, W.; Pdar, K.; Hideshima, T.; Chauhan, D.; Schlossman, R.; Richardson, P; Treon, S.P.; Grewal, I.S.; Munshi, N.C.; Anderson, K.C. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res., 2005, 65, 11712-11720.
54. Lapalombella, R.; Yu, B.; Triantafillou, G.; Liu, Q.; Butchar, J.P.; Lozanski, G.; Ramamunni, A.; Smith, L.L.; Blum, W.; Andritsos, L.; Wang, D.S.; Lehman, A.; Chen, C.S.; Johnson, A.J.; Marucci, G.; Lee, R.J.; Lee, L.J.; Tridandapani, S.; Mathusamy, N.; Byrd, J.C. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 2008, 112, 5180-5189.
55. Zhang, L.; Qian, Z.; Cai, Z.; Sun, L.; Wang, H.; Bartlett, J.B. Yi, Q.; Wang, M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am. J. Hematol., 2009, 84(9), 553-559.
56. Epling-Burnette, P.K.; Bai, F.; Painter, J.S.; Rollison, D.E.; Salih, H.R.; Krusch, M.; Zou, J.; Ku, E.; Zhong, B.; Boulware, D.; Moscinski, L; Wei, S.; Djeu, J.Y.; List, A.F. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood, 2007, 109, 4816-4824.
57. Hideshima, T.; Chauhan, D.; Schlossman, R.; Richardson, P.; Anderson, K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 2001, 20, 4519-4527.
58. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, T.A.; Anderson, K.C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involvesactivation of NF-kappa B. Blood, 1996, 87, 1104-1112.
59. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R.M.; Serve, H.; Berdel, W.E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 2000, 95, 2630-2636.
60. Gupta, D.; Treon, S.P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.T.; Lin, B.; Lentzsch, S.; Davies, F.E.; Chauhan, D.; Schlossman, R.L.; Richardson, P.; Ralph, P.; Wu, L.; Payvandi, F.; Muller, G.; Stirling, D.I.; Anderson, K.C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001, 15, 1950-1961.
61. Akiyama, M.; Hideshima, T.; Hayashi, T.; Tai, Y.T.; Mitsiades, C.S.; Mitsiades, N.; Chauhan, D.; Richardson, P.; Munshi, N.C.; Anderson, K.C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res., 2002, 62(13), 3876-3882.
62. Hideshima, T.; Nakamura, N.; Chauhan, D.; Anderson, K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 2001, 20(42), 5991-6000.
63. Geitz, H.; Handt, S.; Zwingenberger, K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 1996, 31, 213-21. doi: 10.1016/0162-3109(95)00050-X
64. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91, 4082-5. doi: 10.1073/pnas.91.9.4082
65. Bauer, K.S.; Dixon, S.C.; Figg, W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is speciesdependent. Biochem. Pharmacol., 1998, 55(11), 1827-1834.
66. Yaccoby, S.; Johnson, C.L.; Mahaffey, S.C.; Wezeman, M.J.; Barlogie, B.; Epstein, J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood, 2002, 100(12), 4162-4168.
67. Singhal S, MEHTA J, DESIKAN R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341(21):1565-1571.
68. Neben K, Moehler TM, Kraemer A et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol. (2001) 115(3):605-608.
69. Lentzsch S, Leblanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia (2003) 17(1):41-44.
70. Dredge K, Marriott JB, MacDonald CD et al. Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br. J. Cancer. (2002) 87(10):1166-1172
71. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA, 2006, 103, 19478-19483
72. Giagounidis, A.A.; Germing, U.; Haase, S.; Hildebrandt, B.; Schlegelberger, B.; Schoch, C.; Wilkens, L.; Heinsch, M.; Willems, H.; Aivado, M.; Aul, C. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 2004, 18, 113-119. doi: 10.1038/sj.leu.2403189.
73. Buesche, G. Anti-Angiogenic in vivo effect of lenalidomide in MDS with del 5 q chromosome abnormality. Oral Abstratc Session ASCO 2007.
74. Yaccoby, S. Osteoblastogenesis and tumor growth in myeloma. Leuk. Lymphoma., 2010, 51(2), 213-220.
75. Oshima, T.; Abe, M.; Asano, J.; Hara, T.; Kitazoe, K.; Sekimoto, E.; Tanak, Y.; Shibata, H.; Hashimoto, T.; Ozaki, S.; Kido, S.; Inoue, D.; Matsumoto, T. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 2005, 106, 3160-3165.
76. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med., 2003, 349, 2483-2494.
77. Ehrlich, L.; Chung, H.Y.; Ghobrial, I.; Choi, S.J.; Morandi, F.; Colla, S.; Rizzoli, V.; Roodman, G.D.; Giuliani, N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 2005, 106, 1407-1414.
78. Anderson, G.; Gries, M.; Kurihara, N.; Honjo, T.; Anderson, J.; Donnenberg, V.; Donnenberg, A.; Ghobrial, I.; Mapara, M.Y.; Stirling, D.; Roodman, D.; Lentzsch, S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 2006, 107, 3098-3105.
79. Breitkreutz, I.; Tai, Y.; Li, X.; Coffey, R.; Raab, M.S.; Song, W.; Hideshima, T.; Chauhan, D.; Munshi, N.; Anmderson, K.C. Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications. Blood, 2006, 108, 3485.
80. Breitkreutz, I.; Raab, M.S.; Vallet, S.; Hideshima, T.; Raje, N.; Mitsiades, C.; Chauhan, D.; Okawa, Y.; Munshi, N.C.; Richardson, P.G.; Anderson, K.C. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia, 2008, 22, 1925-1932. doi: 10.1038/leu.2008. 174.
81. Giuliani, N.; Morandi, F.; Tagliaferri, S.; Lazzaretti, M.; Bonomini, S.; Crugnola, M.; Mancini, C.; Martella, E.; Ferrari, L.; Tabillo, A; Rizzolli, V. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood, 2007, 110, 334-338.
82. Trojan, A.; Tinguely, M.; Vallet, S.; Seifert, B.; Jenni, B.; Zippelius, A.; Witzens-Harig, M.; Mechtersheimer, G.; Ho, A.; Goldschmidt, H.; Jäger, D.; Boccadoro, M.; Ladetto, M. Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med. Wkly., 2006, 136(25-26), 400-403.
83. Ladetto, M.; Vallet, S.; Trojan, A.; Dell'Aquila, M.; Monitillo, L.; Rosato, R.; Santo, L.; Drandi, D.; Bertola, A.; Falco, P.; Cavallo, F.; Ricca, I.; De Marco, F.; Mantoan, B.; Bode-Lesniewska, B.; Pagliano, G.; Francese, R.; Rocci, A.; Astolfi, M.; Compagno, M.; Mariani, S.; Godio, L.; Marino, L.; Ruggeri, M.; Omedè, P.; Palumbo, A.; Boccadoro, M. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood, 2005, 105, 4784-4791.
84. Zhang, M.; Abe, Y.; Matsushima, T.; Nishimura, J.; Nawata, H.; Muta, K. Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk. Lymphoma, 2005, 46, 425-433.
85. Payvandi, F.; Wu, L.; Haley, M.; Schafer, P.H.; Zhang, L.H.; Chen, R.S., Muller, G.W.; Stirling, G.W. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol., 2004, 230, 81-88.
86. Hideshima, T.; Chauhan, D.; Shima, Y.; Raje, N.; Davies, F.E.; Tai, Y.T.; Treon, S.P.; Lin, B.; Schlossman, R.L.; Richardson, P.; Muller, G.; Stirling, D.I.; Anderson, K.C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96, 2943-2950.
87. Mitsiades, N.; Mitsiades, C.S.; Poulaki, V.; Anderson, K.C.; Treon, S.P. Intracellular regulation of tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood, 2002, 99, 2162-2171.
88. Rajkumar, S.V.; Jacobus, S.; Callander, N.; Fonseca, R.; Vesole, D.; Williams, M. et al. Phase III trial of lenalidomide plus high dose dexamethasone versus lenalidomide plus lowdosedexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. ASCO Ann. Meeting Proc. Part 2007, 25(June 20 Supplement): LBA8025
89. Mitsiades, N.; Mitsiades, C.S.; Poulaki, V.; Chauhan, D.; Richardson, P.G.; Hideshima, T.; Munshi, N.C.; Treon, S.P.; Anderson, K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99, 4525-4530.
90. Rajen, N.; Kumar, S.; Hideshima, T.; Ishitsuka, K.; Chauhan, D.; Mitsiades, C.; Podar, K.; Le Gouill, S.; Richardson, P.; Munshi, N.C.; Stirling, D.I.; Antin, J.H.; Anderson, K.C. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104, 4188-4193.
91. Jakubowiak, A.; Richardson, P.; Zimmerman, T.; Alsina, M.; Lonial, S.; Kendall, T.; et al. A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: preliminary results. Multiple myeloma research consortium (MMRC) trial. Haematologica, 2007, 92 (Suppl 2): Abstract no. PO-606.
92. Verhelle, D.; Corral, L.G.; Wong, K.; Mueller, J.H.; Parseval, J.M.; Jensen-Pergakes, K.; Schafer, P.H.; Chen, R.; Glezer, E.; Ferguson, G.D.; Lopez-Girona, A.; Muller, G.W.; Brady, H.A.; Chan, K.W.H. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res., 2007, 67(2), 746-55.
93. Pellagatti, A; Jadersten, M.; Forsblom, A.M.; Cattan, H.; Christensson, B.; Emanuelsson, E.K.; Merup, M.; Nilsson, L.; Samuelsson, J.; Sander, B.; Wainscoat, J.S.; Boultwood, J.; Hellstrom-Lindberg, E. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5qsyndrome patients. Proc Natl Acad Sci USA. 2007, 104, 11406-11. doi: 10.1073/pnas.0610477104
94. Chanan-Khan, A. Pro-Apoptotic effect of Lenalidomide in patients with Chronic Lymphocytic Leukemia is possibly mediated through interruption of Phosphatidylinositol pathway. Blood, 2006, (ASH annual Meeting Abstracts).
95. Lapalombella, R.; Andritsos, L.; Liu, Q.; May, S.E.; Browning, R.; Pham, L.V.; Blum, K.A.; Blum, W.; Ramanunni, A.; Raymond, C.A.; Smith, L.L.; Lehman, A.; Mo, X.; Jarjoura, D.; Chen, C.S.; Ford, R.J.; Rader, C.; Muthusamy, N.; Johnson, A.; Byrd, J.C. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood, 2010, 115(13), 2619-2629.
96. Andritsos, L.; Johnson, A.J.; Lozanski, G.; Blum, W.; Kefauver, C.; Awan, F.; Smith, L.L.; Lapalombella, R.; May, S.E.; Raymond, C.A.; Wang, D.S.; Knight, R.D.; Rippert, A.S.; Lehman, A.; Jarjoura, D.; Chen, D.S.; Byrd, J.C. Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2008, 26, 2519-2525
97. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Görgün, G.; Le Dieu, R.; Blum, W.; Byrd, J. C.; Gribben, J. G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest., 2008, 118(7), 2427-2437.